GLPwatch
In type 2 diabetes, liraglutide reduced CV events at 5 y vs. glargine, glimepiride, or sitagliptin.
Ann Intern Med · 2023
Last updated 2026-05-28In a study of 5,047 adults with type 2 diabetes, those taking liraglutide had a lower rate of cardiovascular events over 5 years compared to those taking glargine, glimepiride, or sitagliptin. Specifically, 11.4% of participants on liraglutide experienced cardiovascular events, compared to 12.5% on glargine, 13.1% on glimepiride, and 12.7% on sitagliptin.
AI summary of the abstract below.
| Journal | Ann Intern Med, 2023 |
|---|---|
| Citations | 1 |
| Relative citation ratio | 0.20 |
| NIH percentile | 13 |
| Molecules | liraglutide |
| Conditions studied | Type 2 Diabetes, Cardiovascular Risk Reduction |
Abstract
GRADE Study Research Group; Nathan DM, Lachin JM, Buse JB, et al. N Engl J Med. 2022;387:1075-88. 36129997.
Verbatim abstract via PubMed 36592466 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.